The study, led by R.J. Graf, A. Edwards, M.A. Crowley and colleagues, focuses on “time to blood culture positivity,” the interval between collecting a blood sample and detecting microbial growth in the laboratory. Blood cultures remain a central tool for diagnosing sepsis, including late-onset sepsis in newborns. When bacteria or fungi are present, they may multiply in the culture bottle and trigger an automated signal. If no growth is detected after a defined period, clinicians must decide whether antibiotics can safely be stopped, even though a negative result cannot provide absolute certainty.

That decision is especially consequential in the NICU. Newborns, particularly those born very prematurely or with very low birth weight, have immature immune systems and limited physiological reserves. Infection may present with nonspecific changes in breathing, temperature, feeding, heart rate or blood pressure. Because the consequences of missing sepsis can be catastrophic, clinicians often begin broad-spectrum antibiotics while awaiting culture results. Yet many infants who receive this emergency treatment ultimately do not have a confirmed infection.

The resulting exposure is not harmless. Antibiotics can disrupt the developing intestinal microbiome, the complex community of microorganisms that influences digestion, immune development and resistance to invading pathogens. In premature infants, alterations in this ecosystem have been associated with concerns including intestinal inflammation and vulnerability to antimicrobial-resistant organisms. Prolonged or repeated treatment can also expose infants to medication toxicity and contribute to the wider public-health problem of antibiotic resistance. The clinical challenge is therefore not simply to use antibiotics quickly, but to use them for the shortest safe duration.

A blood culture’s time to positivity is influenced by several technical and biological factors. The number of organisms in the original sample, the volume of blood collected, the type of pathogen and whether antibiotics were given before the sample was obtained can all affect detection. In neonates, the small amount of blood that can safely be drawn creates an additional limitation. A culture containing only a tiny number of microorganisms may take longer to signal than one with a larger initial burden, while prior antimicrobial exposure may suppress growth altogether.

The study’s focus reflects a broader effort to make antibiotic decisions more precise rather than relying on a fixed waiting period for every infant. If the great majority of clinically meaningful bloodstream infections become detectable within a defined window, then continuing antibiotics beyond that point may provide little additional protection for infants who remain stable and whose cultures show no growth. Conversely, if certain organisms or clinical situations regularly require more time, an overly aggressive stopping rule could create unacceptable risk. The value of a time-based approach depends on how accurately it distinguishes these different scenarios.

This is why culture timing cannot be interpreted in isolation. Neonatologists must combine laboratory results with the infant’s clinical condition, the quality of the blood sample, inflammatory markers, the likelihood of infection before testing and the presence of other possible sources of illness. A negative culture does not automatically exclude infection, particularly when the sample volume is inadequate or antibiotics were administered first. The study’s central question is therefore not whether a clock can replace clinical judgment, but whether better evidence about that clock can support safer, more consistent decisions.

The work arrives at a moment when hospitals are increasingly adopting antimicrobial stewardship programs designed specifically for newborn care. These programs seek to reduce unnecessary antibiotic starts and shorten treatment courses without increasing missed infections or complications. In practice, the findings from research on culture positivity could help NICUs develop protocols that define when antibiotics should be reassessed, what additional evidence should be considered and which infants require prolonged observation. Such protocols could also reduce variation between clinicians and institutions, where local habits sometimes determine treatment duration as much as microbiological evidence.

For families, the issue is often experienced as a confusing trade-off: antibiotics may be started urgently, but stopping them can feel risky when a newborn remains medically fragile. Clearer data about when cultures become positive could make those conversations more transparent. It could also encourage hospitals to improve the fundamentals of culture collection, including obtaining an adequate blood volume before treatment whenever clinically possible, because laboratory timing is meaningful only when the initial sample is capable of detecting infection.

By revisiting the timing of blood culture positivity, Graf, Edwards, Crowley and their colleagues place a familiar diagnostic test at the center of a pressing neonatal-care question. The ultimate goal is not simply fewer antibiotic doses, but a more accurate separation between infants who need immediate and sustained treatment and those for whom early therapy can be safely discontinued. In the NICU, where both infection and over-treatment carry real dangers, refining that distinction could turn a laboratory result into a powerful tool for protecting newborn health.

Subject of Research: Time to blood culture positivity and reducing antibiotic exposure in the neonatal intensive care unit (NICU)

Article Title: Revisiting time to blood culture positivity: can we decrease antibiotic exposure in the NICU?

Article References: Graf, R.J., Edwards, A., Crowley, M.A. et al. “Revisiting time to blood culture positivity: can we decrease antibiotic exposure in the NICU?” Journal of Perinatology (2026). https://doi.org/10.1038/s41372-026-02838-z

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02838-z

Keywords: neonatal intensive care, blood culture, time to positivity, neonatal sepsis, antibiotic stewardship, premature infants, antimicrobial exposure, microbiology

Blood culture positivity time has long served as a fulcrum around which decisions about antibiotic therapy duration pivot. In NICUs, where neonates are particularly susceptible to infections, timely and accurate diagnosis is vital. Typically, clinicians wait 48 hours or longer before deciding to discontinue empiric antibiotics when cultures remain negative, a practice rooted in caution but fraught with risks. Prolonged antibiotic exposure carries significant dangers, including alteration of the neonatal microbiome, increased incidence of resistant organisms, and potential toxicities that can compromise developing organs. By revisiting the kinetics of blood culture positivity, the study boldly addresses these risks head-on.

The researchers embarked on a comprehensive evaluation of time-to-positivity (TTP) data derived from neonatal blood cultures, employing sophisticated statistical analyses to dissect the temporal patterns of bacterial detection. They interrogated large datasets from NICU patients, assessing how quickly pathogens rise to detectable levels in automated culture systems. This meticulous approach illuminated a striking revelation: a majority of true bloodstream infections manifest positivity markedly earlier than the conventional 48-hour window, suggesting that current protocols may be unduly protracted.

Crucially, the study pursued a dual aim—not only establishing the statistical robustness of earlier positivity times but also contextualizing these findings within clinical decision-making frameworks. The investigators reviewed outcomes of neonates whose empiric antibiotic courses were curtailed based on rapid negative culture results. Their data demonstrated that shortening the empiric treatment duration by adhering to updated TTP benchmarks did not compromise safety or increase the incidence of missed infections. This finding challenges the entrenched dogma that longer antibiotic courses inherently safeguard neonatal patients.

In the realm of microbiology, time-to-positivity reflects the interplay between pathogen burden, microbial growth rates, and host factors. The automated blood culture systems used in contemporary NICUs continuously monitor bacterial proliferation and flag positivity once thresholds are met. Graf et al.’s analysis revealed that pathogens commonly implicated in neonatal sepsis—such as Group B Streptococcus, E. coli, and Staphylococcus species—often achieve detectability within 24 hours. This temporal window contrasts sharply with the traditionally accepted 48-hour surveillance period, raising important questions about the feasibility of safely revising timing protocols.

The implications of this study extend beyond mere timing adjustments. By establishing evidence-based criteria for earlier cessation of antibiotics, NICUs could witness a substantial reduction in antimicrobial use, a critical step in combating the global menace of antibiotic resistance. Neonates, with their especially fragile physiologies and developing immune systems, stand to benefit enormously from protocols that minimize unnecessary antibiotic exposure. This could translate into reduced incidences of antibiotic-associated complications such as necrotizing enterocolitis, candidiasis, and long-term dysbiosis-related disorders.

Integrating the revised TTP findings into clinical practice will, however, require nuanced adjustments. The study acknowledges that certain high-risk neonates—such as those with extremely low birth weights or those supported by invasive devices—may still necessitate cautious interpretation of culture kinetics. The authors advocate for a stratified risk approach, where rapid culture negativity could be employed confidently in low to moderate-risk populations, while maintaining vigilance in others. This adaptive strategy suggests that one-size-fits-all antibiotic protocols might soon give way to precision guidelines tailored to individual clinical contexts.

The methodology underpinning this research further underscores its significance. Using a multicenter dataset encompassing thousands of neonatal blood culture records ensures that results are both statistically powerful and clinically generalizable. Furthermore, the incorporation of machine learning algorithms enhanced the predictive accuracy of risk stratification models. By correlating early culture negativity with low adverse event rates, the study provides clinicians with robust tools to make informed antibiotic stewardship decisions, balancing safety with therapeutic pragmatism.

Of note, the investigators employed rigorous quality control measures in culture processing, recognizing that culture sensitivity and blood volume are critical determinants of TTP reliability. The study reinforced the importance of collecting adequate blood volumes for culture, which remains a practical challenge in fragile neonates. Enhanced standardization across NICUs regarding blood collection and culture processing protocols emerges as an ancillary benefit of this research, potentially harmonizing care quality across institutions.

Beyond microbiological insights, this study also delves into the broader systemic impacts of reducing unnecessary antibiotic use. The neonatal microbiome, a rapidly evolving frontier of medical science, is acutely sensitive to antibiotic perturbation. Persistently administered antibiotics disrupt colonization patterns, potentially predisposing infants to immune dysregulation, asthma, allergies, and metabolic disorders later in life. By facilitating earlier antibiotic discontinuation, the revised approach championed by Graf and colleagues supports the preservation of microbial homeostasis and promotes healthier lifelong outcomes.

Educational outreach and implementation science will be crucial to translating these findings into day-to-day NICU operations. Despite compelling evidence, changing entrenched clinical behaviors can be challenging. The authors suggest collaboration with infection control teams, antibiotic stewardship committees, and neonatal providers to develop integrated protocols and robust monitoring frameworks. Real-time feedback systems could be instituted to track antibiotic durations and patient outcomes, ensuring that changes in practice do not sacrifice safety.

Moreover, the economic implications of shorter antibiotic courses are notable. Reduced antibiotic consumption decreases pharmacy costs, and shortened hospital stays related to antibiotic-related complications can further optimize resource utilization. Although the study does not directly address cost analyses, the emergent narrative suggests that interventions based on revisited TTP data could yield significant health economic benefits—an important consideration in healthcare systems worldwide.

Technological evolution plays a supporting role in these advances. Rapid blood culture detection platforms, increasingly sophisticated and sensitive, enable clinicians to gain actionable results more quickly than ever before. Supplementing traditional cultures with adjunctive molecular diagnostics may in future allow further refinements in infection detection and antibiotic stewardship, building on the foundational insights of this research.

In conclusion, the study by Graf et al. represents a critical pivot point in neonatal infectious disease management. The longstanding 48-hour blood culture observation window is ripe for reassessment, with compelling evidence now favoring earlier discontinuation of empiric antibiotics in many NICU patients. By harmonizing microbiological realities with clinical urgency, this research paves the way for safer, more judicious antibiotic use. The potential to mitigate antimicrobial resistance while safeguarding neonatal health renders this work both timely and potentially transformative.

As the field of neonatology increasingly embraces precision medicine principles, studies such as this highlight the power of data-driven refinements to standard care protocols. The balance between preventing catastrophic infections and minimizing iatrogenic harms demands that every clinical decision be informed by the best available evidence. Revisiting time to blood culture positivity offers a model approach, demonstrating that long-held dogmas in medicine should always be subject to rigorous reexamination in the service of improved patient outcomes.

Future inquiries will undoubtedly build upon these findings, exploring the interplay of host genetics, immune status, and pathogen virulence in shaping culture positivity dynamics. Additionally, prospective interventional trials will be essential to validate and optimize implementation strategies for revised antibiotic durations. The ongoing quest to perfect neonatal care is propelled forward by research that combines technical precision with clinical pragmatism—qualities embodied in this landmark study.

Subject of Research: Neonatal blood culture time-to-positivity and its impact on antibiotic exposure in the NICU.

Article Title: Revisiting time to blood culture positivity: can we decrease antibiotic exposure in the NICU?

Article References:
Graf, R.J., Edwards, A., Crowley, M.A. et al. Revisiting time to blood culture positivity: can we decrease antibiotic exposure in the NICU?. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02629-6

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02629-6